VJHemOnc Podcast Highlights from iwMyeloma 2025: trial updates and practical considerations
May 2, 2025
Join Damian Green, a leader in cellular immunotherapy at the University of Miami, and Rachid Baz, a myeloma specialist at Moffitt Cancer Center, as they dive into the latest breakthroughs in multiple myeloma treatments. They discuss the benefits and challenges of T-cell therapies, including managing side effects and improving access to treatment. There's also a focus on innovative therapies like bispecific antibodies, the importance of personalized medicine, and real patient stories that highlight transformative outcomes.
AI Snips
Chapters
Transcript
Episode notes
CD38 Antibodies in Frontline Therapy
- CD38 monoclonal antibodies have moved into frontline therapy with high response and MRD negativity rates.
- Quadruplet regimens including CD38 antibodies plus VRD or KRD show promise for longer progression-free survival.
Safe Use of CD38 Therapies
- Use subcutaneous administration of CD38 antibodies to minimize infusion reactions.
- Monitor patients closely for infection symptoms, especially pneumonia, and treat promptly.
Belantamab's Practical Advantages
- Belantamab mafodotin is a flexible ADC effective across myeloma therapy lines when dosed properly.
- Adjusting dose and schedule reduces ocular toxicity without losing efficacy.